Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takemasa Tsuji

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Cancer Immunology, Immunotherapy : CII|April 23, 2022
Tcf-1 protects anti-tumor TCR-engineered CD8<sup>+</sup> T-cells from GzmB mediated self-destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Immunology, Immunotherapy : CII|June 6, 2022
Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8<sup>+</sup> T‑cells from GzmB mediated self‑destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Science|June 26, 2003
An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapyTakemasa Tsuji, Kenji Chamoto, Hiromi Funamoto, et al.
Immunology Letters|May 12, 2004
Generation of leukemia-specific T-helper type 1 cells applicable to human leukemia cell-therapyTaku Fujimura, Kenji Chamoto, Takemasa Tsuji, et al.
Cancer Immunology Research|January 8, 2014
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patientsShigehisa Kitano, Takemasa Tsuji, Caillian Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 2010
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificityTakemasa Tsuji, Junko Matsuzaki, Marcus P Kelly, et al.
International Immunology|May 6, 2004
Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunitySatoshi Yamamoto, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Research|January 20, 2004
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cellsKenji Chamoto, Takemasa Tsuji, Hiromi Funamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2010
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerJunko Matsuzaki, Sacha Gnjatic, Paulette Mhawech-Fauceglia, et al.
Cancer Research|December 3, 2004
Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunityYoshinori Suzuki, Daiko Wakita, Kenji Chamoto, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Cancer Immunology, Immunotherapy : CII|April 23, 2022
Tcf-1 protects anti-tumor TCR-engineered CD8<sup>+</sup> T-cells from GzmB mediated self-destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Immunology, Immunotherapy : CII|June 6, 2022
Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8<sup>+</sup> T‑cells from GzmB mediated self‑destructionBrendan Zangari, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Science|June 26, 2003
An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapyTakemasa Tsuji, Kenji Chamoto, Hiromi Funamoto, et al.
Immunology Letters|May 12, 2004
Generation of leukemia-specific T-helper type 1 cells applicable to human leukemia cell-therapyTaku Fujimura, Kenji Chamoto, Takemasa Tsuji, et al.
Cancer Immunology Research|January 8, 2014
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patientsShigehisa Kitano, Takemasa Tsuji, Caillian Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 2010
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificityTakemasa Tsuji, Junko Matsuzaki, Marcus P Kelly, et al.
International Immunology|May 6, 2004
Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunitySatoshi Yamamoto, Takemasa Tsuji, Junko Matsuzaki, et al.
Cancer Research|January 20, 2004
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cellsKenji Chamoto, Takemasa Tsuji, Hiromi Funamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2010
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerJunko Matsuzaki, Sacha Gnjatic, Paulette Mhawech-Fauceglia, et al.
Cancer Research|December 3, 2004
Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunityYoshinori Suzuki, Daiko Wakita, Kenji Chamoto, et al.
Pageof 6